迪安診斷(300244.SZ):新冠病毒抗原檢測試劑盒被列入歐盟通用白名單
格隆匯12月27日丨迪安診斷(300244.SZ)公佈,近日,公司下屬子公司杭州迪安生物技術有限公司(“迪安生物”)研發的新冠病毒抗原檢測試劑盒被列入歐盟衞生安全委員會HSC Common List(歐盟通用白名單)。
此次被列入歐盟衞生安全委員會HSC Common List,説明迪安生物的新冠病毒抗原檢測試劑盒的性能在歐盟得到進一步有效驗證,標誌着該產品從臨牀數據到技術文檔都充分受到歐盟HSC的認可,對於該產品在歐盟區域的銷售具有積極作用。公司海外銷售產品品類得到進一步擴充,擴寬了公司新冠檢測產品的海外應用場景,對於迪安生物海外銷售及國際業務拓展具有積極作用。公司將進一步加快國際化步伐,努力拓展國際市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.